Back

Efficacy and safety of edoxaban vs. warfarin in patients with atrial fibrillation and hepatic disease: Insights from the ENGAGE AF-TIMI 48 trial

28 August 2017 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster session 4 - Stroke prevention Atrial fibrillation (AF) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Arman Qamar

Brigham and Women's Hospital, Boston (United States of America)

53 More presentations in this session

Presentation thumbnail
Doctor A. Tyminska (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Doctor M. Gupta (Toronto, CA)
Abstract
Presentation thumbnail
Professor H. Bonnemeier (Luebeck, DE)
Abstract Slides
Presentation thumbnail
Ms D. Loikas (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Doctor J. Franchino-Elder (Ridgefield, US)
Abstract

Access the full session

Session thumbnail
Poster session 4 - Stroke prevention

The Event

Event poster

ESC Congress 2017

28 August 2017 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources